NEW YORK, NY (October 17, 2008) - Schrödinger announced today that Dr. Paul S. Anderson has joined the company's Scientific Advisory Board. Dr. Anderson is a venerable figure in medicinal chemistry with a proven track record of leading successful drug discovery and development programs. During his distinguished career at Merck, Dr. Anderson and coworkers developed TRUSOPT, the first topical carbonic anhydrase inhibitor for treating glaucoma, and ZOCOR, a frequently prescribed drug for lowering cholesterol levels. Dr. Anderson also focused on new chemotherapy for AIDS, resulting in CRIXIVAN and SUSTIVA. "I'm happy to join Schrödinger's Scientific Advisory Board because I'm impressed with what the company has accomplished so far and the direction they're headed in tackling important, real-life problems in medicinal chemistry," said Dr. Anderson.

"Paul is an impressive scientist who has devoted his career to developing novel therapies for a wide range of diseases," said Professor Richard A. Friesner , Schrödinger's founder and Scientific Advisory Board Chairman. "His wealth of knowledge and experience is invaluable to us." Schrödinger's President Dr. Ramy Farid agrees, "Paul provides us with the guidance we need as we expand our product development to create new tools for medicinal chemists."

"Schrödinger has assembled a balanced suite of computational tools for lead discovery and optimization," said Dr. Anderson, "I look forward to lending my years of experience at the bench to help the team at Schrödinger continue to develop practical solutions to accelerate the drug discovery process." In addition to Professor Friesner, Dr. Anderson will join Dr. Mark Murcko of Vertex Pharmaceuticals, Professors Bruce Berne, Ronald Breslow, and Barry Honig of Columbia University, Professor Wayne Guida of Moffitt Cancer Center, Professor Matt Jacobson of UCSF, Professor Bill Jorgensen of Yale, and Professor Ron Levy of Rutgers on Schrödinger's Scientific Advisory Board .

Dr. Anderson is the recipient of numerous awards, including the 2006 Priestley Medal, the highest honor of the American Chemical Society. In addition, Dr. Anderson is the Chairman of the Gordon Research Conferences Board of Trustees, and has served as President of the American Chemical Society, Chairman of the Medicinal Chemistry Division of ACS, Chairman of the Gordon Research Conference on Medicinal Chemistry, Chairman of the NIH Study Section on Bioorganic Chemistry and Natural Products, as well as being a member of the National Advisory General Medicinal Sciences Council of the National Institutes of Health and the National Research Council Board on Chemical Sciences and Technology.

Contact:
Shi-Yi Liu
(503) 299-1150
Shi-Yi.Liu@schrodinger.com